TCT Receives Patent on Therapeutic Monoclonal Antibody Targeting Pancreatic Cancer
/EINPresswire.com/ SANTA ROSA, CA, (1/18/12) --Targeted Cancer Therapeutics LLC (TCT) announced that its anti-CEACAM6 product received the U.S. Designation of Patent Number 8,038,996. The patent claims allow for a method of treating various types of cancer using an anti-CEACAM6 monoclonal antibody that induces apoptosis in cancer cells.
"We designed a monoclonal antibody that binds to CEACAM protein over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung ovarian cancers and certain childhood leukemias." stated Daruka Mahadevan MD, Ph.D., Chief Scientific Officer of TCT. "It is a highly specific monoclonal antibody designed to disrupt CEACAM6 function and was tailored for a superior safety profile. There is an unmet need for effective treatments of pancreatic cancer, as it is uniformly lethal and new treatment paradigms are urgently needed."
The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.
In 2010, there were over 40,000 pancreatic cancer cases, of which there were over 39,300 deaths, providing a dismal prognosis. This is attributable to a lack of early diagnosis and effective treatments. Most patients present with unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDA), with a median overall survival of 12 and 6 months respectively.
For more information on Targeted Cancer Therapeutics LLC and its products,
Email info@targetedcancer.com or visit www.targetedcancer.com
About Targeted Cancer Therapeutics (TCT)
Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.
Contact Information
William Mulert
President
(707) 477-7022
bmulert@targetedcancer.com
"We designed a monoclonal antibody that binds to CEACAM protein over-expressed on >95% of pancreatic cancer patients. CEACAM6 is also over-expressed in colon cancers, as well as breast, lung ovarian cancers and certain childhood leukemias." stated Daruka Mahadevan MD, Ph.D., Chief Scientific Officer of TCT. "It is a highly specific monoclonal antibody designed to disrupt CEACAM6 function and was tailored for a superior safety profile. There is an unmet need for effective treatments of pancreatic cancer, as it is uniformly lethal and new treatment paradigms are urgently needed."
The antibody was designed as a humanized anti-CEACAM6 single chain variable fragment (scFv) based on the murine Mab 13-1. PEGylation of the glycine-serine linker was used to enhance plasma half-life. The scFv bound CEACAM6 with high affinity, exhibited cytotoxic activity and induced dose-dependent PARP-cleavage in KRas mutated and wild type pancreatic cancer cell lines. Murine PDA xenograft models treated with low doses of humanized scFv-PEG alone elicited tumor growth inhibition, which was enhanced in combination with gemcitabine. Immunohistochemistry of harvested tumors showed significant apoptosis, with inhibition of angiogenesis and proliferation.
In 2010, there were over 40,000 pancreatic cancer cases, of which there were over 39,300 deaths, providing a dismal prognosis. This is attributable to a lack of early diagnosis and effective treatments. Most patients present with unresectable and/or metastatic pancreatic ductal adenocarcinoma (PDA), with a median overall survival of 12 and 6 months respectively.
For more information on Targeted Cancer Therapeutics LLC and its products,
Email info@targetedcancer.com or visit www.targetedcancer.com
About Targeted Cancer Therapeutics (TCT)
Targeted Cancer Therapeutics is a privately held biopharmaceutical company located in California. The company has an exclusive license agreement with the University of Arizona for several products designed for the treatment of cancers. TCT is actively seeking investment capital to further develop its products.
Contact Information
William Mulert
President
(707) 477-7022
bmulert@targetedcancer.com
Follow us
What people say
“We have generated many, many press clippings and improved our SEO ranking from the services that EIN Presswire provides us. Easy and simple way to upload and distribute our press releases. I would recommend their services.”
— Chris Morris, Marketing Manager of Mountz Inc.
“I have been using the EIN Press Release service for more than three years in entertainment & health care industries. Their account managers and the placement of my press releases online has been above reproach reaching mainstream journalists to help further client and brand visibility. I highly recommend this service for global notoriety and am thankful I made that first call.“
— Monica Anders PR Strategist 25 Years!
Our Partners
Press releases
- Fairfax County, VA; Iowa State & Utah State Labs Receive APHL Healthiest Laboratory Awards [23 May 2012] Marketwire
© 2005-2012